- Home
- QNTM vs ACXP Comparison
QNTM vs ACXP Comparison
Compare QNTM & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNTM
- ACXP
- Stock Information
- Founded
- QNTM 1998
- ACXP 2017
- Country
- QNTM Canada
- ACXP United States
- Employees
- QNTM N/A
- ACXP N/A
- Industry
- QNTM
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- QNTM
- ACXP Health Care
- Exchange
- QNTM NYSE
- ACXP Nasdaq
- Market Cap
- QNTM 8.7M
- ACXP 8.4M
- IPO Year
- QNTM N/A
- ACXP 2021
- Fundamental
- Price
- QNTM $6.91
- ACXP $0.40
- Analyst Decision
- QNTM
- ACXP Strong Buy
- Analyst Count
- QNTM 0
- ACXP 1
- Target Price
- QNTM N/A
- ACXP $12.00
- AVG Volume (30 Days)
- QNTM 919.6K
- ACXP 135.9K
- Earning Date
- QNTM 05-06-2025
- ACXP 05-13-2025
- Dividend Yield
- QNTM N/A
- ACXP N/A
- EPS Growth
- QNTM N/A
- ACXP N/A
- EPS
- QNTM N/A
- ACXP N/A
- Revenue
- QNTM N/A
- ACXP N/A
- Revenue This Year
- QNTM N/A
- ACXP N/A
- Revenue Next Year
- QNTM N/A
- ACXP N/A
- P/E Ratio
- QNTM N/A
- ACXP N/A
- Revenue Growth
- QNTM N/A
- ACXP N/A
- 52 Week Low
- QNTM $2.70
- ACXP $0.30
- 52 Week High
- QNTM $33.80
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- QNTM 53.04
- ACXP 48.44
- Support Level
- QNTM $5.91
- ACXP $0.36
- Resistance Level
- QNTM $6.43
- ACXP $0.45
- Average True Range (ATR)
- QNTM 0.72
- ACXP 0.02
- MACD
- QNTM -0.05
- ACXP 0.02
- Stochastic Oscillator
- QNTM 56.19
- ACXP 97.32
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.